CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - USD ($) $ in Thousands |
Common Stock
Common stock
|
Common Stock
Class A common stock
|
Additional Paid-In Capital |
Accumulated Other Comprehensive Income (Loss) |
Accumulated Deficit |
Convertible preferred stock |
Total |
| Balance at the beginning of the period at Dec. 31, 2018 |
|
|
|
|
|
$ 104,774
|
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2018 |
|
|
|
|
|
1,323,506
|
|
| Increase (Decrease) in Temporary Equity |
|
|
|
|
|
|
|
| Issuance of Series D preferred stock, net of issuance costs of $158 |
|
|
|
|
|
$ 37,274
|
|
| Issuance of Series D preferred stock, net of issuance costs of $158 (in shares) |
|
|
|
|
|
257,000
|
|
| Balance at the end of the period at Mar. 31, 2019 |
|
|
|
|
|
$ 142,048
|
|
| Balance at the end of the period (in shares) at Mar. 31, 2019 |
|
|
|
|
|
1,580,506
|
|
| Balance at the beginning of the period at Dec. 31, 2018 |
$ 0
|
|
$ 3,327
|
$ (3,720)
|
$ (59,982)
|
|
$ (60,375)
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2018 |
1,006,595
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
| Foreign currency translation adjustment, net of tax |
|
|
|
(736)
|
|
|
(736)
|
| Stock-based compensation expense |
|
|
383
|
|
|
|
383
|
| Net loss |
|
|
|
|
(9,329)
|
|
(9,329)
|
| Balance at the end of the period at Mar. 31, 2019 |
$ 0
|
|
3,710
|
(4,456)
|
(69,311)
|
|
(70,057)
|
| Balance at the end of the period (in shares) at Mar. 31, 2019 |
1,006,595
|
|
|
|
|
|
|
| Balance at the beginning of the period at Dec. 31, 2018 |
|
|
|
|
|
$ 104,774
|
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2018 |
|
|
|
|
|
1,323,506
|
|
| Balance at the beginning of the period at Dec. 31, 2018 |
$ 0
|
|
3,327
|
(3,720)
|
(59,982)
|
|
(60,375)
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2018 |
1,006,595
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
| Foreign currency translation adjustment, net of tax |
|
|
|
|
|
|
(435)
|
| Net loss |
|
|
|
|
|
|
(21,408)
|
| Balance at the end of the period at Jun. 30, 2019 |
$ 3
|
$ 0
|
221,576
|
(4,156)
|
(81,390)
|
|
136,033
|
| Balance at the end of the period (in shares) at Jun. 30, 2019 |
21,588,756
|
3,819,732
|
|
|
|
|
|
| Balance at the beginning of the period at Dec. 31, 2018 |
|
|
|
|
|
$ 104,774
|
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2018 |
|
|
|
|
|
1,323,506
|
|
| Balance at the beginning of the period at Dec. 31, 2018 |
$ 0
|
|
3,327
|
(3,720)
|
(59,982)
|
|
(60,375)
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2018 |
1,006,595
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
| Net loss |
|
|
|
|
|
|
(43,000)
|
| Balance at the end of the period at Dec. 31, 2019 |
$ 3
|
$ 0
|
225,568
|
(4,653)
|
(103,019)
|
|
117,899
|
| Balance at the end of the period (in shares) at Dec. 31, 2019 |
21,746,392
|
3,819,732
|
|
|
|
|
|
| Balance at the beginning of the period at Mar. 31, 2019 |
|
|
|
|
|
$ 142,048
|
|
| Balance at the beginning of the period (in shares) at Mar. 31, 2019 |
|
|
|
|
|
1,580,506
|
|
| Increase (Decrease) in Temporary Equity |
|
|
|
|
|
|
|
| Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering |
|
|
|
|
|
$ (142,048)
|
|
| Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering (in shares) |
|
|
|
|
|
(1,580,506)
|
|
| Balance at the beginning of the period at Mar. 31, 2019 |
$ 0
|
|
3,710
|
(4,456)
|
(69,311)
|
|
(70,057)
|
| Balance at the beginning of the period (in shares) at Mar. 31, 2019 |
1,006,595
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
| Issuance of common stock upon initial public offering at $14.00 per share for cash, net of issuance costs of $9,386 |
$ 1
|
|
74,614
|
|
|
|
74,615
|
| Issuance of common stock upon initial public offering at $14.00 per share for cash, net of issuance costs of $9,386(in shares) |
6,000,000
|
|
|
|
|
|
|
| Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering |
$ 2
|
$ 0
|
142,046
|
|
|
|
142,048
|
| Conversion of Series A, B, C and D preferred stock into common stock upon initial public offering(in shares) |
14,582,161
|
3,819,732
|
|
|
|
|
|
| Foreign currency translation adjustment, net of tax |
|
|
|
300
|
|
|
300
|
| Stock-based compensation expense |
|
|
1,206
|
|
|
|
1,206
|
| Net loss |
|
|
|
|
(12,079)
|
|
(12,079)
|
| Balance at the end of the period at Jun. 30, 2019 |
$ 3
|
$ 0
|
221,576
|
(4,156)
|
(81,390)
|
|
136,033
|
| Balance at the end of the period (in shares) at Jun. 30, 2019 |
21,588,756
|
3,819,732
|
|
|
|
|
|
| Balance at the beginning of the period at Dec. 31, 2019 |
$ 3
|
$ 0
|
225,568
|
(4,653)
|
(103,019)
|
|
117,899
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2019 |
21,746,392
|
3,819,732
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
| Issuance of common stock upon exercise of stock options |
$ 0
|
|
8
|
|
|
|
8
|
| Issuance of common stock upon exercise of stock options (in shares) |
78,598
|
|
|
|
|
|
|
| Foreign currency translation adjustment, net of tax |
|
|
|
(93)
|
|
|
(93)
|
| Stock-based compensation expense |
|
|
2,094
|
|
|
|
2,094
|
| Net loss |
|
|
|
|
(10,926)
|
|
(10,926)
|
| Balance at the end of the period at Mar. 31, 2020 |
$ 3
|
$ 0
|
227,670
|
(4,746)
|
(113,945)
|
|
108,982
|
| Balance at the end of the period (in shares) at Mar. 31, 2020 |
21,824,990
|
3,819,732
|
|
|
|
|
|
| Balance at the beginning of the period at Dec. 31, 2019 |
$ 3
|
$ 0
|
225,568
|
(4,653)
|
(103,019)
|
|
$ 117,899
|
| Balance at the beginning of the period (in shares) at Dec. 31, 2019 |
21,746,392
|
3,819,732
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
| Issuance of common stock upon exercise of stock options (in shares) |
|
|
|
|
|
|
88,300
|
| Foreign currency translation adjustment, net of tax |
|
|
|
|
|
|
$ (226)
|
| Net loss |
|
|
|
|
|
|
(18,018)
|
| Balance at the end of the period at Jun. 30, 2020 |
$ 3
|
$ 0
|
229,828
|
(4,879)
|
(121,037)
|
|
103,915
|
| Balance at the end of the period (in shares) at Jun. 30, 2020 |
21,834,692
|
3,819,732
|
|
|
|
|
|
| Balance at the beginning of the period at Mar. 31, 2020 |
$ 3
|
$ 0
|
227,670
|
(4,746)
|
(113,945)
|
|
108,982
|
| Balance at the beginning of the period (in shares) at Mar. 31, 2020 |
21,824,990
|
3,819,732
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
| Issuance of common stock upon exercise of stock options |
$ 0
|
|
7
|
|
|
|
7
|
| Issuance of common stock upon exercise of stock options (in shares) |
9,702
|
|
|
|
|
|
|
| Foreign currency translation adjustment, net of tax |
|
|
|
(133)
|
|
|
(133)
|
| Stock-based compensation expense |
|
|
2,151
|
|
|
|
2,151
|
| Net loss |
|
|
|
|
(7,092)
|
|
(7,092)
|
| Balance at the end of the period at Jun. 30, 2020 |
$ 3
|
$ 0
|
$ 229,828
|
$ (4,879)
|
$ (121,037)
|
|
$ 103,915
|
| Balance at the end of the period (in shares) at Jun. 30, 2020 |
21,834,692
|
3,819,732
|
|
|
|
|
|